Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 5Phase 1 4

Status

Withdrawn 2Completed 2Recruiting 1

Sponsor Class

INDUSTRY 11OTHER 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Lymphoid 1

Conditions

Fallopian Tube Neoplasms 2Spinocerebellar Degenerations 1Rectal Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × epacadostat × Clear all
NCT03516708 2026-02-11

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Washington University School of Medicine

Phase 1/2 Recruiting
49 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02166905 2023-02-24

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Roswell Park Cancer Institute

Phase 1/2 Completed
40 enrolled 15 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03322384 2022-02-01

UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

University of California, Davis

Phase 1/2 Completed
20 enrolled 10 charts
Lymphoid

Lymphoma

NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

University of Pittsburgh

Phase 1/2 Withdrawn
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT01982487 2013-12-18

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡